Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Gamma-Delta Pionee | Adicet Bio leads in engineered gamma-delta T cell therapies, with promising candidates for lupus nephritis and renal cell carcinoma in Phase 1 trials |
Financial Fortitude | Strong cash position of $150.4M supports ongoing clinical trials, though rapid cash burn rate poses future funding challenges |
Expanding Horizons | Explore Adicet's ambitious pipeline expansion into multiple autoimmune conditions, showcasing the versatility of its innovative platform |
Market Valuation | With analyst price targets ranging from $4 to $8 per share, Adicet's current trading price of $0.69 presents a potential asymmetric upside opportunity |
Metrics to compare | ACET | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACETPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.5x | −2.9x | −0.5x | |
PEG Ratio | −0.01 | −0.09 | 0.00 | |
Price/Book | 0.5x | 1.2x | 2.6x | |
Price / LTM Sales | - | 6.2x | 3.3x | |
Upside (Analyst Target) | - | 286.0% | 38.7% | |
Fair Value Upside | Unlock | 21.1% | 5.0% | Unlock |